M
M. Campion
Researcher at Biogen Idec
Publications - 6
Citations - 1217
M. Campion is an academic researcher from Biogen Idec. The author has contributed to research in topics: Interferon beta-1a & Pharmacodynamics. The author has an hindex of 6, co-authored 6 publications receiving 1203 citations.
Papers
More filters
Journal ArticleDOI
A longitudinal study of brain atrophy in relapsing multiple sclerosis
Jack H. Simon,Lawrence Jacobs,M. Campion,Richard A. Rudick,Diane Cookfair,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,N. A. Simonian,M. Lajaunie,D. E. Miller,K. E. Wende,A. Martens-Davidson,R. P. Kinkel,Frederick Munschauer,Carol M. Brownscheidle +17 more
TL;DR: In patients with relapsing MS and only mild to moderate disability, significant cerebral atrophy is already developing that can be measured over periods of only 1 to 2 years.
Journal ArticleDOI
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Richard A. Rudick,N. A. Simonian,J. A. Alam,M. Campion,James Scaramucci,Wendy Jones,Michael E. Coats,Donald E. Goodkin,Bianca Weinstock-Guttman,Robert M. Herndon,Michele Mass,John R. Richert,Andres M. Salazar,Frederick Munschauer,Diane Cookfair,Jack H. Simon,Lawrence Jacobs +16 more
TL;DR: NAB directed against IFN-β have in vivo biological consequences in patients with MS and treatment decisions in MS patients treated withIFN- β should take into account development of NAB.
Journal ArticleDOI
Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis
Jack H. Simon,Lawrence Jacobs,M. Campion,K. E. Wende,N. A. Simonian,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,John J. Alam,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Michelle Lajaunie,Anna L. Martens-Davidson,Mary Joel Meyer,Jeanelle Sheeder,Kim Choi,Ann Scherzinger,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +34 more
TL;DR: Once weekly intramuscular IFNβ‐1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long‐term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions.
Journal ArticleDOI
A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β-1a
Jack H. Simon,Julia M. Lull,Lawrence Jacobs,Richard A. Rudick,Diane Cookfair,Robert M. Herndon,John R. Richert,Andres M. Salazar,Jeanelle Sheeder,D. E. Miller,K. McCabe,A. Serra,M. Campion,J. S. Fischer,Donald E. Goodkin,N. A. Simonian,M. Lajaunie,K. E. Wende,A. Martens-Davidson,R. P. Kinkel,Frederick Munschauer +20 more
TL;DR: The development of T1 hypointense lesions is strongly influenced by prior inflammatory disease activity, as indicated by enhancing lesions, and treatment with once weekly IM IFNβ-1a (30 mcg) slows the 2-year accumulation of these lesions in the brain.
Journal ArticleDOI
Comparative Pharmacokinetics and Pharmacodynamics of Two Recomhinant Human Interferon Beta-la (IFNβ-la) Products Administered Intramuscularly in Healthy Male and Female Volunteers
John J. Alam,Susan Goelz,Patrice Rioux,James Scaramucci,Wendy Jones,Arthur McAllister,M. Campion,Mark Rogge +7 more